NCT00439686已完成1 期
A Phase IB/IIA Study of the Saftey and Activity of Intravenous Isophosporamide Mustard (ZIO-201) in Patients With Advanced Sarcoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 53
- 主要终点
- toxicities
研究概览
简要总结
The study of safety of Isophosphoramide Mustard (IPM) in the treatment of advanced sarcoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Single Arm
Experimental
干预措施: ZIO-201 (Drug)
结局指标
主要结局
toxicities
时间窗: 6 months
次要结局
- pharmacokinetics(6 months)
研究者
相似试验
已完成
1 期
A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced CancerAdvanced CancerNCT00421135Alaunos Therapeutics30
终止
1 期
Dose-escalation Study of APG-1387 and Toripalimab in Solid TumorsAdvanced Solid TumorNCT04284488Ascentage Pharma Group Inc.40
Unknown
3 期
Efficacy and Safety Evaluation of the Imescard Compound Water Smartweed OintmentHemorrhoidal DiseaseNCT00935948Hospital de Clinicas de Porto Alegre60
进行中（未招募）
1 期
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid TumorsSolid TumorNCT04606472Sichuan Baili Pharmaceutical Co., Ltd.60
已完成
1 期
A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell CarcinomaMetastatic Melanoma and Merkel Cell CarcinomaNCT01652547Novartis Pharmaceuticals10